be_ixf;ym_202301 d_27; ct_50

Tag: Vaccine

A Stock-Picking Mutation to Beat the Omicron Threat

This is a company that has never made a profit. In fact, it’s never made any money at all. On top of that, analysts expect its per-share losses to double by the end of 2022. Assuming Adagio manages to generate some revenues next year — the market consensus is a minuscule $151 million — it’s already trading at almost 20 times those sales. Why? Because COVID is here to stay … and the search for a response is moving into new areas … quickly.

Read More
  • 1
  • 2

Newsletter Sign Up

Sponsored

CS Care Video

MEET OUR EXPERTS

WHAT READERS ARE SAYING..

“My portfolio has grown from 275k to almost 900k with only investments made with Banyan Hill.”

- David G. (Member since 2018)

“I started with $215,000 in Nov. 2018, It is now over 800,000. So very happy with Banyan Hill Publishing.”

- Larry K.

"You have done once again!! You are reminding me of the GREAT Joe DiMaggio with your consistent hitting!! You knocked this one out of the park!"

- Keith S.